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Abstract
Background: In 2003, the Committee on Safety of Medicines (CSM) advised against treatment with selective serotonin
reuptake inhibitors (SSRIs) other than fluoxetine in children, due to a possible increased risk of suicidal behaviour. This study
examined the effects of this safety warning on general practitioners’ depression diagnosing and prescription behaviour in
children.
Methods and Findings: We identified a cohort of 1,502,753 children (,18 y; registered with GP for .6 m) in The Health
Improvement Network (THIN) UK primary care database. Trends in incidence of depression diagnoses, symptoms and
antidepressant prescribing were examined 1995–2009, accounting for deprivation, age and gender. We used segmented
regression analysis to assess changes in prescription rates. Overall, 45,723 (3%) children had $1 depression-related entry in
their clinical records. SSRIs were prescribed to 16,925 (1%) of children. SSRI prescription rates decreased from 3.2
(95%CI:3.0,3.3) per 1,000 person-years at risk (PYAR) in 2002 to 1.7 (95%CI:1.7,1.8) per 1,000 PYAR in 2005, but have since
risen to 2.7 (95%CI:2.6,2.8) per 1,000 PYAR in 2009. Prescription rates for CSM-contraindicated SSRIs citalopram, sertraline
and especially paroxetine dropped dramatically after 2002, while rates for fluoxetine and amitriptyline remained stable.
After 2005 rates for all antidepressants, except paroxetine and imipramine, started to rise again. Rates for depression
diagnoses dropped from 3.0 (95%CI:2.8,3.1) per 1,000 PYAR in 2002 to 2.0 (95%CI:1.9,2.1) per 1,000 PYAR in 2005 and have
been stable since. Recording of symptoms saw a steady increase from 1.0 (95%CI:0.8,1.2) per 1,000 PYAR in 1995 to 4.7
(95%CI:4.5,4.8) per 1,000 PYAR in 2009.
Conclusions: The rates of depression diagnoses and SSRI prescriptions showed a significant drop around the time of the
CSM advice, which was not present in the recording of symptoms. This could indicate caution on the part of GPs in making
depression diagnoses and prescribing antidepressants following the CSM advice.
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Introduction
Antidepressants (ADs) are commonly prescribed to children and
adolescents for depression, anxiety, and a variety of other disorder
[1]. Selective serotonin reuptake inhibitors (SSRIs), first intro-
duced in the late 1980s, were prescribed to children for depression
on the basis of effectiveness data from trials on adult psychiatric
disorders coupled with other trial data demonstrating the
ineffectiveness of tricyclic antidepressants (TCAs) [2–5]. In the
early 2000s, SSRIs became the preferred treatment for depression
in children rather than tricyclic antidepressants (TCAs) [6].
However, doubts have been cast on the use of specific SSRIs in
children. In October 2002, the BBC aired an episode of the
investigative journalism show ‘Panorama’ which casted doubt on
the safety of the SSRI paroxetine. In response to this, the UK
Medicines and Healthcare Products Regulatory Agency (MHRA)
reanalysed published and unpublished data on paroxetine, and
found that the drug failed to demonstrate significant beneficial
effects, and was associated with a small increase in suicidal
behaviour and ideation [7]. In June 2003, the MHRA hence
advised that paroxetine should not be used to treat depression in
children younger than 18 years [8]. Following this investigation,
the Committee on Safety of Medicines (CSM) reviewed the safety
of all antidepressants in children and adolescents and in December
2003 advised against the initiation of all SSRIs, except fluoxetine
in children [9]. Fluoxetine is the only drug currently licensed to
treat depression in children in the UK as its benefits were deemed
greater than its risks [10,11]. The CSM, however, does
recommend psychotherapies, such as cognitive-behavioural ther-
apy, as first-line treatment for children and adolescents with
depression. The American Food and Drug Authority (FDA)
followed suit in October 2004 and issued a black box warning for
all antidepressants prescribed to children [12].
Following the CSM advice, fewer children and adolescents in
the UK were prescribed antidepressants in primary care [13].
There was a 48% reduction in the initiation of CSM-contraindi-
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However, the use of fluoxetine and non-SSRI antidepressants in
children had not significantly risen during the same period. A
similar pattern was found in a study in Australia, where
antidepressant use, and SSRI use in particular, in children and
adolescents decreased between 2002 and 2005 [14]. In stark
contrast, the use of SSRIs and all antidepressants increased
significantly in adults during the same period.
Time trends in antidepressant prescribing in children have been
described for periods leading up to the CSM advice [1,13], but this
is the first comprehensive study which covers trends in the
recording of depression diagnoses and symptoms, and the
prescription of antidepressants in children and adolescents from
1995 to 2009 in a large UK general practice database.
Methods
Ethics statement
The scheme for THIN to obtain and provide anonymous
patient data to researchers was approved by the National Health
Service South-East Multicenter Research Ethics Committee
(MREC) in 2002 and scientific approval for this study was
obtained from CMD Medical Research’s Scientific Review
Committee in March 2011.
Data Source
Approximately 98% of the population in the UK is registered
with a general practitioner [15]. The Health Improvement
Network (THIN) database is one of the largest national collections
of primary care data and is broadly representative of the general
practice (GP) population in terms of demographics and consulta-
tion behaviour [16]. Participating general practitioners from 497
practices enter clinical information on patients, including demo-
graphics data, diagnoses, and prescriptions so as to offer a
longitudinal medical record for each patient which is available to
researchers as anonymised data [17]. Clinical diagnoses recorded
by GPs on THIN have been shown to be accurate compared with
other reliable sources [18]. The database provides the Townsend
score measure of deprivation, a composite measure of social
deprivation in quintiles (owner occupation, overcrowding, car
ownership, and unemployment) [19]. It is based on patient postal
code and linked to UK census data from 2001 for approximately
150 households in that postal area. We analysed data from 1995 to
2009.
Study population
We identified a cohort of children aged up to 18 years who were
registered with a General Practice which was a part of THIN for
at least six months between January 1995 and December 2009.
Children entered the cohort when they registered with a General
Practice, or, the date when their practice joined the THIN scheme
and met standards for acceptable levels of data recording [20].
Children remained in the cohort until aged 18 years, transfer out
of the practice, date of death or date of last data collection from
the practice.
Measurements
Outcome. We examined entries made of diagnoses and
symptoms of depression. Depression diagnosis codes ranged from
‘dysthymia’ and ‘mild depression’ to ‘recurrent severe major
depression’, but excluded codes that indicated other mental
disorder such as psychosis or anxiety. Depression symptoms relate
to codes indicating depression but are not certain enough to be
classified as a diagnosis, such as ‘symptoms of depression’ or ‘C\O
feeling depressed’. We also examined antidepressants BNF codes
prescribed by the general practitioner at any dose, except for high
dose TCAs (50 mg) that were indicated for nocturnal enuresis [6].
These code lists have been created and used in previous studies
and were developed in line with published methods and reviewed
by a general practitioner [21,22].
Potential confounders. We included information on age,
gender and social deprivation score in our analysis as these are
known to be associated with childhood depression and the
distribution of these variables may change over the 15 year
study period.
Statistical analysis. We described the baseline socio-
demographic characteristics of the cohort using frequency tables.
We calculated annual incidence rates and 95% confidence
intervals (CI) for depression diagnoses, symptoms and
antidepressant prescriptions by dividing the annual number of
incident cases by the total person-years at risk (PYAR) for each
year.
Incidence rate ratios adjusted for gender, age and quintiles of
Townsend deprivation score) were estimated using a Poisson
regression model. The analyses were adjusted for clustering at
practice level.
A Lewis plot [23] was used to explore the association between
time since registration and incidence rates as prior diagnoses might
be registered at or near the time of registration and these ought not
to be included in the incidence rates. The Lewis plots revealed that
there was an increased rate of depression diagnoses, symptoms and
antidepressant prescribing in the first month after registration,
after which the rate of recording dropped to a steady state (results
not shown). To correct for this, we started follow=up one month
after registration.
In order to assess the effects of the CSM advice on
antidepressant prescribing, a segmented regression analysis [24]
was performed using the Jointpoint regression program (version
3.5.1) from the Surveillance Research Program of the US National
Cancer Institute [25]. Jointpoint is statistical software for the
analysis of trends using Jointpoint models [26]. This analysis
allows for identifying points where there is a change in the linear
slope of the trend. The analysis started with the minimum number
of jointpoints (i.e., 0 jointpoints, which is a straight line), and tested
whether one or more jointpoints (up to 4) were statistically
significant and should be added to the model. The models
incorporated estimated variation for each point by using the
standard error of the rate estimate. After identifying the existence
of a change in the trend, a segmented regression was fitted and the
result of the best model was shown graphically. Finally, the
estimated annual percentage of change (APC) and its correspond-
ing 95% CI was computed for each of those trends by fitting a
regression line to the natural logarithm of the rates, using calendar
year as a regression variable [27].
All other analyses were conducted in of Stata, version 11.2
(Stata Corp, College Station, Texas).
Results
In total, 1,502,753 children up to the age of 18 were registered
with their GP for at least one year in The Health Improvement
Network (THIN) UK primary care database. Of these children,
45,723 (3%) children had at least one entry of a depressive
symptom, diagnosis or antidepressant prescription. Of these
children, 17,124 (38%) had a diagnosis of depression, 22,587
(49%) had a record of depressive symptoms, and 25,473 (56%)
were prescribed antidepressants, 16,925 of which were SSRIs
(Figure 1). Most of these antidepressant prescriptions were for
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other antidepressants 771 (3%) of prescriptions (Table 1). Of the
children receiving SSRIs, 4,339 (26%) were not diagnosed with
depression or depression symptoms. Similarly, 7,211 (42%) of
children diagnosed with depression were not prescribed antide-
pressants.
Rates for entries of diagnoses of depression increased from 2.2
(95% CI 1.9–2.5) per 1,000 PYAR in 1995 to 3.0 (95%CI:2.8,3.1)
per 1,000 PYAR in 2002, then dropped to 2.0 (95%CI:1.9,2.1) per
1,000 PYAR in 2005 and have since been relatively constant at
around 2.0 per 1,000 PYAR (Figure 2). Rates for antidepressant
prescribing show a similar pattern: they have gone up from 2.8
(95%CI:2.4,3.1) per 1,000 PYAR in 1995 to 4.5 (95%CI:4.3,4.6)
per 1,000 PYAR in 2002, then dropped to rates similar to the
initial 1995 rates, but have been increasing again since 2005.
Recording of symptoms has seen a dramatic rise from 1.0
(95%CI:0.8,1.2) in 1995 to 4.7 (95%CI:4.5,4.8) per 1,000 PYAR
in 2009.
TCAs were the most common antidepressant prescribed to
children in 1995, but by 1999 SSRIs had overtaken them and have
been the preferred drug type ever since (Figure 3). However, since
2003 there has been a sharp decline in SSRI prescriptions, with
rates decreasing from 3.2 (95%CI:3.0,3.3) per 1,000 PYAR in
2002 to 1.7 (95%CI:1.7,1.8) per 1,000 PYAR in 2005. Since then,
rates have gradually started increasing again. TCA prescription
rates have gradually decreased since 1995, but stopped decreasing
in 2006. Rates for MAOIs and other antidepressants were
negligible (results not shown).
In children aged 3–11 years, girls were less likely than boys to be
diagnosed as depressed (IRR=0.79, 95%CI:0.67,0.92), have
depression symptoms recorded (IRR=0.90, 95%CI:0.84,0.95) or
be prescribed antidepressants (IRR=0.63, 95%CI:0.58,0.69;
Table 2). In children aged 12–18, girls were more likely than boys
to have been diagnosed as depressed (IRR=2.87,
95%CI:2.77,2.97), have symptoms recorded (IRR=2.31,
95%CI:2.23,2.39) or have been prescribed antidepressants
(IRR=2.71, 95%CI:2.63,2.80). When comparing age groups, the
incidence of all three outcomes in the younger age group (3–11 years
old) is only a fraction of that in the older age group (12–18 years old).
Rates for all depression indicators increased with deprivation:
children and adolescents in the most deprived quintile were twice as
likely to be diagnosed as depressed (IRR=2.14, 95%CI:2.03.2.26)
or be prescribed antidepressants (IRR=1.91, 95%CI:1.82,2.00)
compared to children and adolescent in the least deprived quintile.
For depression symptoms, there was an almost 50% increase of
recording in the most deprived compared to the most affluent
children and adolescents (IRR=1.43, 95%CI:1.36,1.50).
Segmented regression analysis
The Jointpoint analysis suggested for SSRIs as a group, there
were two time points were prescription rates changed: 2002 and
2005. Up to 2002 prescription rates for SSRIs had been
significantly increasing nearly 16% from 1995–2002 (Table 3,
Figures 4A & 4B). However, between 2002 and 2005 the rates
were stagnant, followed by a significant increase of nearly 11%
from 2005 to 2009 (Table 3).
Individual SSRIs followed a similar pattern: fluoxetine,
citalopram, paroxetine and sertraline rates all were increasing
from 1995 to the early 2000s before showing a temporary
decrease, or stall, in prescription rates. Paroxetine was the only
SSRI which showed a statistically significant decrease in
prescription rates. Rates for citalopram and sertraline started
increasing again in 2005, while rates for fluoxetine and paroxetine
remained stable (Table 3).
In contrast, rates for TCAs as a group showed a significant
decrease between 1995 and 2006, after which there was no
significant change. Rates for amitriptyline prescriptions showed a
moderate decrease between 1995 and 2006, but started to increase
after this point. Imipramine prescription rates showed a steady
decline over the entire period.
Figure 1. Venn diagram which shows the intersection between depression diagnoses, symptoms and antidepressant prescriptions.
doi:10.1371/journal.pone.0033181.g001
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Key Findings
To our knowledge, this is the first large paediatric database
study to compare depression diagnoses, symptoms and antide-
pressant prescriptions and the effects the CSM advice over a
longer time period in the UK. We have found that prescription
rates of SSRIs as a group decreased from 3.2 per 1,000 person-
years in 2002 to 1.7 per 1,000 person-years in 2005. More
specifically, rates for contra-indicated SSRIs, i.e. citalopram,
Table 1. Study population characteristics by antidepressant (AD).
Characteristic of first-time
new users Individuals by AD drug group
SSRI
(n=16925)
TCA
(n=7777) Other (n=769) MAOI (n=2)
Any AD
(n=25473)
Socio-demographic
Girls 12142 (71.7) 4680 (60.2) 488 (63.5) 1 (50.0) 17311 (68.0)
Most commonly
prescribed drug (#
prescriptions)
Fluoxetine (8157) Amitriptyline (4402) Mirtazapine (320) Moclobemide (2) -
Deprivation quintile
1 (most affluent) 3252 (19.2) 1631 (21.0) 144 (18.7) 1 (50.0) 5028 (19.7)
2 3063 (18.1) 1451 (18.7) 105 (13.7) 0 4619 (18.1)
3 3456 (20.4) 1646 (21.2) 139 (18.1) 0 5241 (20.6)
43 7 3 2
(22.1)
1706 (21.9) 182 (23.7) 0 5620 (22.1)
5 (most deprived) 3195
(18.9)
1259 (16.2) 191 (24.8) 1 (50.0) 4646 (18.2)
Not recorded 227 (1.3) 84 (1.1) 8 (1.0) 0 319 (1.3)
Age groups
3–10 years 179 (1.1) 1577 (20.3) 7 (0.9) 0 (0) 1764 (6.9)
11–14 years 1567 (9.3) 1558 (20.0) 53 (6.9) 1 (50.0) 3192 (19.4)
15–18 years 15179 (89.7) 4642 (59.7) 709 (92.2) 1 (50.0) 20652 (80.7)
Values are numbers (column percentages) unless otherwise indicated.
SSRI=selective serotonin reuptake inhibitor; TCA=tricyclic antidepressant; MAOI=mono-amine oxidase inhibitor; other ADs are: mirtazapine, venlafaxine, flupentixol,
duloxetine, nefazodone and reboxetine.
doi:10.1371/journal.pone.0033181.t001
Figure 2. Trends in the incidence of childhood depression, symptoms and antidepressants from 1995 to 2009.
doi:10.1371/journal.pone.0033181.g002
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rates for fluoxetine remained stable and rates for TCAs were not
affected. The decline in prescription rates was sharpest for
paroxetine. Similar to SSRI prescription rates, rates for depression
diagnoses entries decreased from 3.0 per 1,000 person-years in
2002 to 2.0 per 1,000 person years in 2005. Depression symptom
recording saw a steady increase over the study period, increasing
from 1.0 per 1,000 person-years in 1995 to 4.7 per 1,000 person-
years in 2009. Finally, rates for SSRIs as group and citalopram in
particular, were increasing after 2005.
The decrease in recording of both depression diagnoses and
antidepressant prescriptions after 2002 could indicate caution on
the part of GPs in diagnosing depression and prescribing
antidepressants following the CSM advice. Moreover, GPs might
prefer to record depression symptoms rather than diagnose a child
as depressed. The decrease in contra-indicated SSRIs as opposed
Figure 3. Rates of prescription of Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors (SSRI) in children.
doi:10.1371/journal.pone.0033181.g003
Table 2. Incidence rate ratios (IRR) for diagnosis and symptoms of depression and antidepressant prescriptions stratified by
gender, age group and deprivation.
Multivariable
a: stratified by
age group: 3–11
Multivariable
a: stratified by
age group: 12–18
Multivariable
a: stratified by
deprivation:
Townsend 1 & 2
c
Multivariable
a: stratified by
deprivation:
Townsend 4 & 5
c
IRR (95% CI) P
b IRR (95% CI) P
b IRR (95% CI) P
b IRR (95% CI) P
b
Diagnosed depression
Gender
Boy Reference Reference Reference Reference
Girl 0.79 (0.67–0.92) 0.003 2.87 (2.77–2.97) ,0.001 2.58 (2.44–2.73) ,0.001 2.93 (2.78–3.09) ,0.001
Symptoms of depression
Gender
Boy Reference Reference Reference Reference
Girl 0.90 (0.84–0.95) 0.001 2.31 (2.23–2.39) ,0.001 1.75 (1.67–1.83) ,0.001 2.12 (2.02–2.22) ,0.001
Antidepressant prescription
Gender
Boy Reference Reference Reference Reference
Girl 0.63 (0.58–0.69) ,0.001 2.71 (2.63–2.80) ,0.001 2.26 (2.16–2.36) ,0.001 2.57 (2.47–2.69) ,0.001
aAdjusted for calendar year, gender, deprivation, age and for clustering by general practitioner practice using robust standard errors.
bP based on Wald test.
cA Townsend score of 1 or 2 represents the most affluent patients, while patients with a Townsend score of 4 or 5 live in the most deprived areas.
doi:10.1371/journal.pone.0033181.t002
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advice.
Although the Jointpoint program points to 2002 as the time point
where SSRI rates changed, the observed data shows that rates did
not decrease until after 2003, the year when the CSM advice was
issued. However, prescription rates could have started decreasing
prior to the CSM advice as information regarding the safety and
effectiveness of SSRIs was circulating in the specialist community
before the advice was issued and could have influenced changes in
prescription recommendations. Similarly, the program does not
qualify the small dip in fluoxetine rates around 2005 as statistically
significant. This dip might be related to the requirement of the US
Food and DrugAdministration(FDA)toaddablackboxwarningto
all antidepressants, including fluoxetine and TCAs, about an
increased risk of suicidal behaviour in 2004 [12].
The sharp decline in paroxetine prescription rates could be
related to the advice by the MHRA against the prescribing of
paroxetine specifically. This advice was issued in June 2003,
preceding the overall SSRI advice in December of the same year.
It followed a review of randomised controlled trials that showed
higher rates of suicidal thought and behaviour (but not completed
suicides) in patient who took paroxetine (25 out of 738; 3%),
compared to those who took placebo (8 out of 647; 1%; p for
difference=0.01) [8].
The BBC programme that initially started the controversy
implied that paroxetine (brand name Seroxat) was addictive, had
severe withdrawal symptoms and could increase the risk of suicidal
behaviour [28]. This might have led to patients being biased
against taking paroxetine as a first line of treatment, and making it
difficult to determine whether the sharp decline in paroxetine
Figure 4. Observed and modelled prescription rates for individual (A) Selective Serotonin Reuptake Inhibitors (SSRIs) and (B)
Tricyclic Antidepressants (TCAs).
doi:10.1371/journal.pone.0033181.g004
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of the drug in response to the issues raised in the programme, or
the advice issued by the CSM half a year later.
The increase in SSRI prescription rates after 2005 could
indicate that concerns about a possible suicidality risk associated
with SSRIs have waned. Several studies found no increased risk of
suicidality for SSRIs [29,30], or increases in suicide rates that
coincided with decreases in SSRI prescription rates [31]. In the
US, 2004 saw the largest single-year increase in suicide rates in
adolescents aged 10–19 years [32]. From 1990 to 2003 suicide
rates had been decreased by 28%, but in 2004 they had increased
with 15% from 6.78 to 7.32 per 100,000 people. This might have
led GPs to revaluate prescribing SSRIs to children and
adolescents, although doubts continue to exist regarding the safety
and effectiveness of SSRIs [33,34].
Comparison to other studies
The antidepressant prescription rates we found are similar in
size and trend to those found by a General Practice Research
Database study which studied prescription rates from 1992 to
2001 [1]. We also found similar age and gender effects. Our results
also confirm findings by Murray et al. who found a decrease in
SSRI prescribing in between 2003 and 2004, while prescribing
rates for fluoxetine remained stable [13]. However, the study by
Murray et al. did not assess data for individual drugs, apart from
fluoxetine, whereas our study did take different SSRIs into
account.
A study based on Australian data also found a decrease in
antidepressant use in children, in particular of SSRIs [14]. They
also saw a sharp rise of fluoxetine over time, which we did not find
in the UK. This might be explained by sertraline being the most
commonly prescribed antidepressant in Australia before the SSRI
controversy started, whereas fluoxetine was already the drug of
first choice in the UK before the CSM advice.
Main Strengths and Limitations
The main strength of this study is its sample size that enables
examination of outcomes separately for girls and boys, and by
drug. There is no clear reason to believe the results would differ for
the entire population of UK children.
However, there are also limitations. In using data from general
practices, few children might have been missed out if their
depression was not severe enough to warrant a visit to a GP, or if
they were diagnosed outside a general practice setting, e.g. by a
child psychiatrist. However, a study on depression in adults found
that although incidence rates in the THIN database are lower than
depression rates found in epidemiological studies, associations with
covariates such as gender and deprivation were similar [35]. Also,
non-psychiatric physician’s recognition of depression has been
found to have a limited sensitivity, but a high specificity [36,37].
Childhood depression rates might have been underestimated in
this study, but trends and associations with other variables are
likely to be representative of the general population. Moreover, as
we were specifically interested in the effects of the CSM advice in
primary care settings, this limitation will have only a minimal
effect on our results.
While data on prescriptions is available in the THIN database,
there is no information on dispensing and treatment compliance.
Thus the antidepressant prescription rates we found might not
reflect antidepressant use. However, we aimed to study prescrip-
tion rates in primary care, so this does not affect our estimates.
Conclusions
After 2002, general practitioners decreased their prescribing of
contra-indicated SSRIs, particularly paroxetine. Rates for fluox-
etine, the only SSRI not to be contra-indicated, remained stable.
Depression diagnoses mirrored prescription rates and decreased
between 2002 and 2005, suggesting caution on the side of GPs.
The timing and direction of these trends imply that GPs followed
the CSM advice, although it cannot be ruled out that these trends
resulted from the negative media attention SSRIs received around
the same time. After 2005, rates for all antidepressants, except
paroxetine, started recovering. This is in line with results from
observational studies that found no increased risk of suicidal
behaviour with SSRIs.
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Table 3. Annual percentage change (APC) for selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) as
groups and individual drugs.
APC 1 (95% CI) Period APC 2 (95% CI) Period APC 3 (95% CI) Period
SSRIs 15.8* (8.5–23.6) 1995–2002 219.7 (236.2–1.0) 2002–2005 10.6* (3.1–18.8) 2005–2009
Fluoxetine 11.6 (20.4–25.1) 1995–2001 21.8 (24.8–1.3) 2001–2009
Citalopram
1 37.7 (24.7–98.9) 1999–2002 222.0 (251.1–45.4) 2002–2005 29.0* (14.4–45.4)2005–2009
Paroxetine
2 67.9 (227.1–286.9) 1995–1997 22.2 (212.2–9.1) 1997–2002 269.1* (284.2–
39.5)
2002–2005
Sertraline
3 20.5* (6.1–37.0) 1996–2002 229.4 (254.2–9.0) 2002–2005 4.3 (211.3–22.6)2005–2009
TCAs 29.5* (210.3–8.7) 1995–2006 6.5 (1.0–12.2) 2006–2009
Amitriptyline 21.8 (23.8–0.3) 1995–2006 11.9* (2.3–22.3) 2006–2009
Imipramine 217.1* (218.6–15.6) 2006–2009
*Annual percentage change (APC) is statistically significant (p,0.05) different from 0.
1Observations start in 1999 for citalopram as prescription rates were negligible (,10 prescriptions a year) before this year.
2Observations stop in 2005 for paroxetine as it is only prescribed sporadically (,5 prescriptions a year) after this time point.
3Observations start in 1996 for sertraline as prescription rates were negligible (,10 prescriptions a year) before this year.
doi:10.1371/journal.pone.0033181.t003
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